AIM Vaccine Co., Ltd. Class H (HK:6660) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
AIM Vaccine Co., Ltd. has announced the submission of pre-application for clinical trials of two mRNA vaccines targeting Respiratory Syncytial Virus and Shingles/Herpes Zoster. The move aligns with the company’s strategy to leverage mRNA technology and tackle diseases with significant market potential, as RSV vaccines are expected to hit a global market size of $16.7 billion by 2030, and Shingles vaccines may reach $23.9 billion. AIM Vaccine is at the forefront of mRNA vaccine development in China, with a robust R&D system and GMP-compliant production facilities poised to rapidly industrialize and commercialize these vaccines upon clinical approval.
For further insights into HK:6660 stock, check out TipRanks’ Stock Analysis page.